Nine years interval between first and second bone marrow transplantations and subsequent long-term survival--a case of acute myeloid leukemia with MLL-AF6 fusion gene.
Yasuhisa
Y
Yokoyama
Kazumi
K
Suzukawa
Yasushi
Y
Okoshi
Toru
T
Nanmoku
Naoshi
N
Obara
Terukazu
T
Enami
Yuichi
Y
Hasegawa
Shigeru
S
Chiba
D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002999:Clone Cells / Q000737:chemistry; D003131:Combined Modality Therapy; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D017710:Lymphocyte Transfusion; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D014411:Neoplastic Stem Cells / Q000737:chemistry; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D012086:Reoperation; D013997:Time Factors; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; C447400:MLL-AF6 fusion protein, human; D015514:Oncogene Proteins, Fusion; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D014750:Vincristine; D000079982:Gemtuzumab; D011239:Prednisolone; C015019:enocitabine; D015122:Mercaptopurine; D003630:Daunorubicin